LeonaBio, Inc. - Common Stock (LONA)

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027

On Track to Complete Enrollment of the Phase 3 ELAINE-3 clinical trial in 4Q 2026 with Topline Data Expected in 2H 2027

Introduces brelgometon as the International Nonproprietary Name (INN) for ATH-1105

BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in San Diego, CA.

Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations

Seasoned leaders bring deep experience in oncology and neurology drug development, corporate strategy, operational execution, and capital markets as company continues to advance clinical pipeline

Management to be Joined by Two Clinical Leaders in the Breast Cancer Field 

Results showed lasofoxifene protected against hormone withdrawal-induced bone loss and maintained a robust anti-tumor response in primary and metastatic animal models of ER+ breast cancer

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1-Mutations

Brings more than 25 years of biopharma business development and corporate strategy expertise